Role of the Funny Current Inhibitor Ivabradine in Cardiac Pharmacotherapy: A Systematic Review

American Journal of Therapeutics
Sarah E PetiteVincent F Mauro

Abstract

The pharmacology, pharmacokinetics, efficacy and safety of ivabradine are reviewed. Ivabradine is an oral medication that directly and selectively inhibits the hyperpolarization-activated cyclic-nucleotide gated funny (If) current in the sinoatrial node resulting in heart rate reduction. It has a plasma elimination half-life of 6 hours and is administered twice daily. Ivabradine is extensively metabolized by cytochrome P450 3A4, and its metabolism is affected by inducers and inhibitors of the 3A4 enzyme. Studies in patients with heart failure indicate that ivabradine improves surrogate markers such as exercise tolerance. The results of (1) phase III trial demonstrated ivabradine significantly reduced heart failure hospitalizations but had no effect on mortality. Ivabradine has been extensively evaluated for coronary artery disease wherein (2) large trials was shown to have no mortality benefit. Ivabradine has been associated with improved symptoms in stable chronic angina pectoris. Ivabradine has been evaluated for other cardiovascular conditions including tachycardias of various natures, arrhythmia prevention postcardiac surgery, in acute coronary syndrome, and for heart rate control during coronary computed tomography angiogr...Continue Reading

References

Jun 6, 2000·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·S B DuffullL Aarons
Jun 27, 2002·The Journal of General Physiology·Annalisa BucchiDario DiFrancesco
Oct 26, 2002·American Journal of Physiology. Heart and Circulatory Physiology·Patrice ColinAlain Berdeaux
Oct 22, 2003·The Journal of Pharmacology and Experimental Therapeutics·Patrice ColinAlain Berdeaux
Aug 4, 2005·The International Journal of Cardiovascular Imaging·Filippo CademartiriGabriel P Krestin
Oct 11, 2005·European Heart Journal·Jean-Claude TardifUNKNOWN INITIATIVE Investigators
Apr 28, 2006·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Dario DiFrancesco
Jan 11, 2007·British Journal of Pharmacology·L CervettoC Gargini
Sep 25, 2007·Cardiology·Lorenzo López-BescósRamón Martos
Jun 3, 2009·Annals of Internal Medicine·Finlay A McAlisterPaul W Armstrong
Jul 14, 2010·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Leonardo CalòFrancesco Fedele
Sep 8, 2010·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Domenico VitaleLuigi Tritapepe
Sep 23, 2010·Naunyn-Schmiedeberg's Archives of Pharmacology·Stephan ZellerhoffStefan Kääb
Oct 19, 2010·American Journal of Physiology. Heart and Circulatory Physiology·Claudio CeconiRoberto Ferrari
Nov 11, 2010·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Claire McDonaldJulia L Newton
Nov 26, 2010·International Journal of Cardiology·Andrea I GuaricciMatteo Di Biase
Nov 30, 2010·International Journal of Cardiology·C CeconiUNKNOWN BEAUTIFUL Echo-BNP Investigators
Jan 21, 2011·The American Journal of Cardiology·Michal TenderaUNKNOWN BEAUTIFUL Investigators
Mar 4, 2011·Journal of Clinical Pharmacy and Therapeutics·L VlaseS E Leucuta
Jul 19, 2011·International Journal of Cardiology·Maurizio VolterraniGiuseppe M C Rosano
Oct 21, 2011·The American Journal of Cardiology·Philipp PichlerBonni Syeda
May 12, 2012·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Michael BöhmLuigi Tavazzi
Jul 10, 2012·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Pawel PtaszynskiJerzy K Wranicz
Nov 10, 2012·International Journal of Cardiology·Jean-Claude TardifUNKNOWN ASSOCIATE Investigators

❮ Previous
Next ❯

Citations

Mar 4, 2017·International Journal of Cardiology·Giampaolo NiccoliFilippo Crea
May 20, 2016·Journal of Pharmacy Practice·Shreya Patel, Keith Veltri
Aug 11, 2019·Current Topics in Medicinal Chemistry·Yue ZhouKun Sun

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.